The Function and Mechanism of Anti-Inflammatory Factor Metrnl Prevents the Progression of Inflammatory-Mediated Pathological Bone Osteolytic Diseases
Nan Liu,Jinlei Dong,Lianxin Li,Dongsheng Zhou,Fanxiao Liu
DOI: https://doi.org/10.2147/jir.s455790
IF: 4.5
2024-03-12
Journal of Inflammation Research
Abstract:Nan Liu, Jinlei Dong, Lianxin Li, Dongsheng Zhou, Fanxiao Liu Department of Orthopedics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China Correspondence: Fanxiao Liu, Department of Orthopedics, Shandong Provincial Hospital affiliated to Shandong First Medical University, No. 324, Road Jing Wu Wei Qi, Jinan, Shandong, 250021, People's Republic of China, Tel +86-15069058755, Email Metrnl, recently identified as an adipokine, is a secreted protein notably expressed in white adipose tissue, barrier tissues, and activated macrophages. This adipokine plays a pivotal role in counteracting obesity-induced insulin resistance. It enhances adipose tissue functionality by promoting adipocyte differentiation, activating metabolic pathways, and exerting anti-inflammatory effects. Extensive research has identified Metrnl as a key player in modulating inflammatory responses and as an integral regulator of muscle regeneration. These findings position Metrnl as a promising biomarker and potential therapeutic target in treating inflammation-associated pathologies. Despite this, the specific anti-inflammatory mechanisms of Metrnl in immune-mediated osteolysis and arthritis remain elusive, warranting further investigation. In this review, we will briefly elaborate on the role of Metrnl in anti-inflammation function in inflammation-related osteolysis, arthritis, and pathological bone resorption, which could facilitate Metrnl's clinical application as a novel therapeutic strategy to prevent bone loss. While the pathogenesis of elbow stiffness remains elusive, current literature suggests that Metrnl likely exerts a pivotal role in its development. Keywords: osteolysis, bone resorption, bone loss, Metrnl, arthritis, stiff elbow Imbalance of bone metabolism disrupts the physiological function of osteoblasts, osteocytes and osteomacs. This disruption transforms into a pathological condition characterized by progressive bone resorption. Inflammation plays a significant role in this impairment, particularly in various osteolytic bone diseases, where it predominantly shifts the balance towards bone resorption. 1 A variety of chronic inflammatory bone diseases have been shown to be associated with physiological osteolysis, including rheumatoid arthritis (RA), spondylarthritis, osteoporosis, periodontitis, bone metastasis of malignant tumor, periprosthetic osteolysis due to aseptic loosening. 2,3 Multiple immune-related molecules have been proved to play a crucial role in bone metabolism, such as IL-1β, IL-6, IL-10, IL-17 and TNF-α. These cytokines, serving as primary stimulators of osteoclastogenesis, can upregulate the expression of crucial factors involved in osteoclast differentiation, which is a key driver in the progression of pathological bone resorption. Metrnl (IL-41, Meteorin-like, Subfatin, Cometin), a secreted protein expressed in white adipose tissue, 4 barrier tissues, 5,6 and activated macrophages, 5 has been confirmed as a adipokine, neurotrophic, and anti-inflammatory cytokine. This factor demonstrates a multitude of physiological functions by activating various intracellular signaling pathways across different cell types including adipocytes, macrophages, myocytes and cardiomyocytes, such as the promotion of neurite outgrowth, 7 improvement of cognitive dysfunction, 8 inflammation inhibition, 5,7 regulation of energy homeostasis, 7,9 and insulin sensitivity, 7,10 enhancement of the browning of white adipose tissue, 7 skeletal muscle regeneration, 11 and heart protection. 12–14 Current research suggests that Metrnl has potential to be biomarker and therapeutic target for diseases associated with inflammation. Nonetheless, theanti-inflammatory properties and mechanism in immune inflammation-related osteolysis and arthritis remains not fully understood, and further investigation is necessary to elucidate its potential role in these conditions. Recent studies have highlighted that Metrnl play a regulatory role in bone metabolism and immune inflammation. Multiple studies focused on the correlation of Metrnl and bone arthritis associated with metabolism 15–17 or inflammation, including arthritis 18–21 and osteolysis. 3,22 This review aims to briefly elaborate on the anti-inflammatory function of Metrnl in inflammation-related osteolysis, arthritis, and pathological bone resorption, which could explore the potential of Metrnl as a novel therapeutic strategy in preventing these diseases. Metrnl is increasingly recognized as a novel immunoregulatory cytokine intricately linked to inflammatory processes. 5,20 Both the expression of Metrnl and its circulating concentrations sh -Abstract Truncated-
immunology